Literature DB >> 31801907

FGF23 expression is stimulated in transgenic α-Klotho longevity mouse model.

Zhousheng Xiao1, Gwendalyn King2, Salvatore Mancarella3, Undral Munkhsaikhan4, Li Cao1, Chun Cai1, Leigh Darryl Quarles1.   

Abstract

Observations in transgenic α-Klotho (Kl) mice (KlTg) defined the antiaging role of soluble Klotho (sKL130). A genetic translocation that elevates sKL levels in humans is paradoxically associated with increased circulating fibroblast growth factor 23 (FGF23) levels and the potential of both membrane KL (mKL135) and sKL130 to act as coreceptors for FGF23 activation of fibroblast growth factor receptors (FGFRs). Neither FGF23 expression nor the contributions of FGF23, mKL135, and sKL130 codependent and independent functions have been investigated in KlTg mice. In the current study, we examined the effects of Kl overexpression on FGF23 levels and functions in KlTg mice. We found that mKL135 but not sKL130 stimulated FGF23 expression in osteoblasts, leading to elevated Fgf23 bone expression and circulating levels in KlTg mice. Elevated FGF23 suppressed 1,25(OH)2D and parathyroid hormone levels but did not cause hypophosphatemic rickets in KlTg mice. KlTg mice developed low aldosterone-associated hypertension but not left ventricular hypertrophy. Mechanistically, we found that mKL135 and sKL130 are essential cofactors for FGF23-mediated ERK activation but that they inhibited FGF23 stimulation of PLC-γ and PI3K/AKT signaling. Thus, increased longevity in KlTg mice occurs in the presence of excess FGF23 that interacts with mKL and sKL to bias FGFR pathways.

Entities:  

Keywords:  Bone Biology; Cardiovascular disease

Year:  2019        PMID: 31801907      PMCID: PMC6962016          DOI: 10.1172/jci.insight.132820

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  87 in total

Review 1.  Endocrine functions of bone in mineral metabolism regulation.

Authors:  L Darryl Quarles
Journal:  J Clin Invest       Date:  2008-12-01       Impact factor: 14.808

2.  Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy.

Authors:  Ming Chang Hu; Mingjun Shi; Nancy Gillings; Brianna Flores; Masaya Takahashi; Makoto Kuro-O; Orson W Moe
Journal:  Kidney Int       Date:  2017-01-25       Impact factor: 10.612

3.  Klotho inhibits angiotensin II-induced cardiac hypertrophy, fibrosis, and dysfunction in mice through suppression of transforming growth factor-β1 signaling pathway.

Authors:  Jieqiong Ding; Qiong Tang; Binhua Luo; Lijun Zhang; Li Lin; Lu Han; Miaomiao Hao; Mingyue Li; Liangzhu Yu; Mincai Li
Journal:  Eur J Pharmacol       Date:  2019-07-17       Impact factor: 4.432

4.  Targeted deletion of Klotho in kidney distal tubule disrupts mineral metabolism.

Authors:  Hannes Olauson; Karolina Lindberg; Risul Amin; Ting Jia; Annika Wernerson; Göran Andersson; Tobias E Larsson
Journal:  J Am Soc Nephrol       Date:  2012-08-09       Impact factor: 10.121

5.  Aging-related renal injury and inflammation are associated with downregulation of Klotho and induction of RIG-I/NF-κB signaling pathway in senescence-accelerated mice.

Authors:  Yi Zeng; Ping-Han Wang; Mao Zhang; Jun-Rong Du
Journal:  Aging Clin Exp Res       Date:  2015-05-19       Impact factor: 3.636

6.  Klotho converts canonical FGF receptor into a specific receptor for FGF23.

Authors:  Itaru Urakawa; Yuji Yamazaki; Takashi Shimada; Kousuke Iijima; Hisashi Hasegawa; Katsuya Okawa; Toshiro Fujita; Seiji Fukumoto; Takeyoshi Yamashita
Journal:  Nature       Date:  2006-10-29       Impact factor: 49.962

7.  Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate.

Authors:  Jian Xie; Joonho Yoon; Sung-Wan An; Makoto Kuro-o; Chou-Long Huang
Journal:  J Am Soc Nephrol       Date:  2014-12-04       Impact factor: 10.121

8.  Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells.

Authors:  Tijana Krajisnik; Peyman Björklund; Richard Marsell; Osten Ljunggren; Göran Akerström; Kenneth B Jonsson; Gunnar Westin; Tobias E Larsson
Journal:  J Endocrinol       Date:  2007-10       Impact factor: 4.286

9.  Differential Regulatory Role of Soluble Klothos on Cardiac Fibrogenesis in Hypertension.

Authors:  Xue Liu; Yuanjian Chen; Cody W McCoy; Tieqiang Zhao; Darryl L Quarles; Min Pi; Syamal K Bhattacharya; Gwendalyn King; Yao Sun
Journal:  Am J Hypertens       Date:  2016-08-19       Impact factor: 2.689

10.  A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia.

Authors:  Zhousheng Xiao; Demian Riccardi; Hector A Velazquez; Ai L Chin; Charles R Yates; Jesse D Carrick; Jeremy C Smith; Jerome Baudry; L Darryl Quarles
Journal:  Sci Signal       Date:  2016-11-22       Impact factor: 8.192

View more
  9 in total

Review 1.  A Land of Controversy: Fibroblast Growth Factor-23 and Uremic Cardiac Hypertrophy.

Authors:  Jing-Fu Bao; Pan-Pan Hu; Qin-Ying She; Aiqing Li
Journal:  J Am Soc Nephrol       Date:  2020-06-11       Impact factor: 10.121

Review 2.  Microglia as the Critical Regulators of Neuroprotection and Functional Recovery in Cerebral Ischemia.

Authors:  Bhakta Prasad Gaire
Journal:  Cell Mol Neurobiol       Date:  2021-08-30       Impact factor: 4.231

3.  Soluble α-klotho and heparin modulate the pathologic cardiac actions of fibroblast growth factor 23 in chronic kidney disease.

Authors:  Christopher Yanucil; Dominik Kentrup; Isaac Campos; Brian Czaya; Kylie Heitman; David Westbrook; Gunars Osis; Alexander Grabner; Adam R Wende; Julian Vallejo; Michael J Wacker; Jose Alberto Navarro-Garcia; Gema Ruiz-Hurtado; Fuming Zhang; Yuefan Song; Robert J Linhardt; Kenneth White; Michael S Kapiloff; Christian Faul
Journal:  Kidney Int       Date:  2022-05-02       Impact factor: 18.998

4.  Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling.

Authors:  Brian Czaya; Kylie Heitman; Isaac Campos; Christopher Yanucil; Dominik Kentrup; David Westbrook; Orlando Gutierrez; Jodie L Babitt; Grace Jung; Isidro B Salusky; Mark Hanudel; Christian Faul
Journal:  Elife       Date:  2022-03-18       Impact factor: 8.713

5.  Klotho Modulates Pro-Fibrotic Activities in Human Atrial Fibroblasts through Inhibition of Phospholipase C Signaling and Suppression of Store-Operated Calcium Entry.

Authors:  Yuan Hung; Cheng-Chih Chung; Yao-Chang Chen; Yu-Hsun Kao; Wei-Shiang Lin; Shih-Ann Chen; Yi-Jen Chen
Journal:  Biomedicines       Date:  2022-07-01

6.  The role of microglial/macrophagic salt-inducible kinase 3 on normal and excessive phagocytosis after transient focal cerebral ischemia.

Authors:  Ke Wang; Chenran Wang; Di Chen; Yichen Huang; Jiaying Li; Pengju Wei; Ziyu Shi; Yue Zhang; Yanqin Gao
Journal:  Cell Mol Life Sci       Date:  2022-07-21       Impact factor: 9.207

Review 7.  Pathophysiology and genetics of salt-sensitive hypertension.

Authors:  Dina Maaliki; Maha M Itani; Hana A Itani
Journal:  Front Physiol       Date:  2022-09-13       Impact factor: 4.755

8.  FGF23 protects osteoblasts from dexamethasone-induced oxidative injury.

Authors:  Feng Ji; Xiaohui Hu; Wenhao Hu; Yue-Dong Hao
Journal:  Aging (Albany NY)       Date:  2020-10-14       Impact factor: 5.682

Review 9.  Osteocytic FGF23 and Its Kidney Function.

Authors:  Rafiou Agoro; Pu Ni; Megan L Noonan; Kenneth E White
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-28       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.